Markets

AptarGroup's Aptar Pharma Reveals CE Marking For LuerVax

Oct 14, 2026 · 05:05 PM ET· updated 56m ago

Aptar Pharma, part of AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its LuerVax® intranasal delivery device and

Why It Matters

Aptar Pharma got official approval for a new nose spray device called LuerVax. This shows the company is moving forward with new tools that doctors and patients might use.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ATR120.27

+1.06 (+0.89%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.